Skip to content
DataLookout
Menu

NIGHTCAPNCT07918053

A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Mean number of moderate-to-severe migraine days per evaluable night-shift-related observation window
Timeframe: Up to 8 weeks (Treatment Period 1 and Treatment Period 2)

Secondary (4)

Mean number of headache days per evaluable night-shift-related observation window
Number of moderate-to-severe migraine attacks during night shifts
Mean number of acute migraine medication use days
Change from baseline in Migraine-Specific Quality of Life Questionnaire (MSQoL v2.1) scores

Arms and interventions

Sequence A: Rimegepant Situational Prevention then Standard CareExperimental

"Treatment Period 1: Rimegepant 75 mg ODT situational prevention. Treatment Period 2: Standard care."

Sequence B: Standard Care then Rimegepant Situational PreventionActive comparator

Treatment Period 1: Standard care. Treatment Period 2: Rimegepant 75 mg ODT situational prevention.

Drugs: Rimegepant 75 mg ODT

Other: Standard Care

Sites

1 site in 1 country

  • Chinese People's Liberation Army General Hospital, First Medical CenterBeijing, Beijing Municipality, China